Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research.
November 13, 2023
By: Anthony Vecchione
Charles River Laboratories International, Inc. and Aitia, a company involved in the application of Causal AI and Digital Twins, entered into a strategic agreement that gives Aitia access to Logica, Charles River’s Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology. Aitia will deploy Logica across their portfolio of novel drug targets with the aim of advancing drug candidates for neurological indications, including Alzheimer’s, Parkinson’s, and Huntington’s diseases and cancers, including prostate cancer and multiple myeloma. “Unraveling the complex genetic and molecular circuitry of neurodegenerative disorders is critical to the discovery of treatments that significantly slow or reverse these devastating diseases,” said Colin Hill, CEO and Co-founder of Aitia. “I do not believe we will get there without the insights from our Digital Twins, which now combined with the advantages of Logica, positions Aitia to rapidly translate our discoveries into novel drug candidates. We are excited to join forces with Charles River, leveraging their decades of industry expertise in research to fuel our R&D efforts.” Julie Frearson, corporate senior vice president and chief scientific officer, Charles River said, “Combining Aitia’s Digital Twins with Logica’s next-generation solution stands to transform the discovery and development of novel therapeutics for neurological diseases and oncology. The research landscape for Alzheimer’s, Parkinson’s, and Huntington’s has moved slowly in recent years, and we are excited for the impact that this combined AI solution can deliver to patients.” In addition, Charles River and Aitia have signed a strategic partnership agreement focused on the development of a patient-derived xenograft (PDX) Digital Twin to predict the best tumor models for in vivo oncology research. The partnership will combine Charles River’s disease-relevant PDX data and expertise with Aitia’s Digital Twin technology to develop PDX Digital Twins in several cancer types. As part of the partnership, Charles River has made an equity investment in Aitia.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !